Background
The accuracy of subjective risk perception is a matter of concern in breast cancer development. The objective of this study was to evaluate the accuracy of self-perceived risk assessment of breast cancer development and compared to actual risk in Iranian women.
Methods
The demographic, clinical, and reproductive characteristics of 800 women aged 35–85 years were collected with an in-person interview. The self-perceived risk and the actual risk were assessed using the visual analog scale (VAS) and he Gail model respectively. Gail’s cutoff of 1.66% risk was used to categorize the estimated 5-year actual risk as low/average risk ( 1.66%) and high risk (≥ 1.66). In low/average risk, if the self-perceived risk actual risk, then individuals were considered as overestimating. Similarly, in high-risk women, if the perceived risk actual risk, then, the subjects were labeled as under-estimate; otherwise, it was labeled as accurate. The Kappa statistics wer
(1)
- Cybrexa and NCI to collaborate on clinical development of Cybrexa s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors -
NEW HAVEN, Conn., Feb. 24, 2021 (GLOBE NEWSWIRE) Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health. Under terms of the agreement, Cybrexa and the NCI will collaborate on pre-clinical and potential clinical development of Cybrexa s lead therapeutic candidate, CBX-12 (alphalex-exatecan).
-16 In these articles, as in others, terminology, usage, and word choice are critically important, especially when describing people and when discussing race and ethnicity. Inclusive language supports diversity and conveys respect. Language that imparts bias toward or against persons or groups based on characteristics or demographics must be avoided.
The indistinct construct of racial and ethnic categories has been increasingly acknowledged, and the important sensitivities and controversies related to use of these terms in medical and health research, education, and practice have been progressively recognized. Accordingly, for articles published in medical and science journals, language and terminology must be accurate, clear, and precise, and must reflect fairness, equity, and consistency in use and reporting of race and ethnicity.
Heartburn Raises Odds for Esophageal, Larynx Cancers
By Amy Norton
HealthDay Reporter
MONDAY, Feb. 22, 2021 (HealthDay News) People with chronic heartburn may face increased risks of several rare types of cancer, a large U.S. government study shows.
Researchers found that among more than 490,000 Americans aged 50 and up, those with gastroesophageal reflux disease (GERD) had about twice the risk of developing cancers of the esophagus or larynx (also known as the voice box).
GERD, or acid reflux, occurs when stomach acids chronically escape into the esophagus, which is the muscular tube connecting the throat and the stomach. The most common symptom is heartburn.
Share this article
Share this article
ROCKVILLE, Md., Feb. 18, 2021 /PRNewswire/ The National Foundation for Cancer Research (NFCR) announced today that the 2021 Szent-Györgyi Prize for Progress in Cancer Research will be awarded to Tak W. Mak, Ph.D., senior scientist at the Princess Margaret Cancer Centre and university professor at the University of Toronto, and Mark M. Davis, Ph.D., professor of microbiology and immunology at the Stanford University School of Medicine, for their breakthrough discoveries of the structure of T-cell receptor (TCR) and pioneering research in deciphering the mechanisms of T-cell recognition and development. These discoveries have formed a critical part of contemporary immuno-oncology and the molecular foundation for life-saving CAR (chimeric antigen receptor) T-cell therapies, a novel T-cell-based immunotherapy approach already approved by the U.S. Food and Drug Administration (FDA) for the treatment of several types of blood cancer.